Navigation Links
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Date:8/20/2007

ystemic formulation of humanized form of Sphingomab(TM)) is an antibody against S1P that holds promise for the treatment of cancer and other diseases. A second product candidate, iSONEP(TM) (the ocular formulation of humanized Sphingomab), has demonstrated superior results in various preclinical AMD models. Lpath's third product candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2(TM) drug-discovery engine, which the company is using to add to its pipeline. For more information, visit http://www.Lpath.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that required clinical trials will be successful, necessary regulatory approvals will be obtained, or the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of therapeutic drugs, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on research grants, current and future competition, and other risks described from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances aris
'/>"/>

SOURCE Lpath, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MISSISSAUGA, ON , May 29, 2015 /CNW/ ... COV), an advanced medical technologies company, is delighted ... quarter ended March 31, 2015, which includes revenue ... for the quarter of $264,340. Revenue from advanced wound ... ended March 31, 2015 increased 24% to $1,742,672 ...
(Date:5/29/2015)... 29, 2015  Epic Sciences announced today that the ... metastatic castrate resistant prostate cancer patients, at the ... Clinical Oncology. This application expands the investigational utility ... platform to characterize circulating tumor cell (CTC) ... patients have heterogeneous clonal CTC populations harboring separate ...
(Date:5/29/2015)... May 29, 2015  World-renowned prostate surgeon and New York ... the benefit of MR/Ultrasound Fusion-Guided Biopsy for detecting ... Prostate Cancer Center at Lenox Hill Hospital is the ... in New York City . We,ve seen ... prostate cancers. The use of an MRI makes for a ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... enzyme that stitches all-important,molecular adjustments onto proteins contorts ... Sept. 18 St. Jude Children,s,Research Hospital investigators ... array of proteins would instantly be reduced to ... for proteins to,"accessorize" in order to regulate their ...
... Analysis Shows HUMIRA Effectively Treats Adult Patients with ... Duration of Disease, ... PARIS, Sept. 18 More psoriasis patients,achieve ... compared to patients who interrupt their therapy, according ...
Cached Medicine Technology:St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins 2St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins 3Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 2Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 3Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 4Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 5Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 6Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 7Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 8
(Date:5/30/2015)... 2015 The iconic American actor, and ... hosting a new segment on Medical Malpractice. This segment ... malpractice in the health care field. , According to ... medical malpractice suits were filed, roughly only 20% of ... out of court, while the remaining 30% were tossed ...
(Date:5/30/2015)... “ Milli the Snail ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... engages and educates children. , Interactive mobile games for children ... content and games they are playing are doing much for ...
(Date:5/30/2015)... Nevada (PRWEB) May 30, 2015 Venus ... of acne scars, large pores, deep wrinkles, stretch marks, ... licensed medical professional, such as Dr. F. Victor Rueckl ... of the clinical trials in Las Vegas. This body ... technology into a system that delivers proven results through ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 Displays and ... that has lowered the price of hanging signs ; ... Hanging signs that hang down from ceiling rigging points at ... over the trade show floor. These signs are very ... there are additional costs for installation and dismantle labor and ...
(Date:5/29/2015)... May 29, 2015 Based in St. Louis, ... awareness shirts for a couple of months now and ... latest release, which reads “I’m not misbehaving, I have Autism, ... the parent’s of an autistic child in order to start ... , Not only are they raising awareness through the autism ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2
... uninsured accounted for almost 1 out of 5 ... -- An estimated 50 million, or 42 percent, of ... hospital emergency departments were billed to the Medicaid and ... Thursday. , Uninsured patients accounted for nearly 18 percent ...
... , , ABA program will ... CALDWELL, N.J., July 31 Caldwell College will launch the ... (ABA), a well developed scientific discipline that is best known for ... Caldwell,s program was recently approved by the New Jersey Commission ...
... July 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases,Inc. (HTDS:PK), ... MEVAC-DTaP (Diphtheria, Tetanus and Acellular,Pertussis Combined Vaccine, adsorbed) had ... The sample analysis is expected to be completed,within the ... Terry Yuan CEO of HTDS said (sic) "We welcome ...
... 31 As the world prepares for a probable ... Pittsburgh researchers are controlling the spread of infectious diseases ... (NIH) grant to establish a Center of Excellence in ... the NIH,s Modeling of Infectious Disease Agent Study (MIDAS) ...
... July 31, 2009 Raytheon Company (NYSE: RTN ... public health-led team of first responders and hospital personnel in ... information. , , The EPTS, ... of victims during mass casualty incidents by providing selected patient ...
... expect meds to relieve stress, personal troubles, researchers caution, ... growing number of Americans now have a positive opinion ... About five out of six people surveyed felt psychiatric ... also expected the medications could help people deal with ...
Cached Medicine News:Health News:ER Visits Mostly by Medicare, Medicaid Recipients 2Health News:Caldwell College Receives Approval to Launch First Ph.D. for Applied Behavior Analysis-Autism Treatment in New Jersey 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 3Health News:Pitt receives $13.4 million NIH grant to create virtual models for epidemics 2Health News:Raytheon to Provide California First Responders and Healthcare Personnel Electronic Patient Tracking System 2Health News:Psych Drugs Gaining Widespread Acceptance 2Health News:Psych Drugs Gaining Widespread Acceptance 3
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
... an elastic belt to help lift the weight ... Apron features "all around protection to cover you ... wearing and removing a breeze. For additional back ... - they reduce pressure on the vertebrae and ...
Unshielded...
... II EEG system is a fully digital 32-channel ... any practice or hospital need. It can be ... a laptop computer for out-of-lab data collection, or ... custom designed carts that will hold a high ...
Medicine Products: